Expertise in
5
conditions

Manuel Borrego-Ruiz

Sevilla, AN, ES 
Expertise in
5
conditions
Sevilla, AN, ES 
OverviewLocationsClinical Research

Overview

Manuel Borrego-Ruiz practices in Sevilla, Spain. Mr. Borrego-Ruiz is highly rated in 5 conditions, according to our data. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Diarrhea, Agranulocytosis, and Mastectomy.

His clinical research consists of co-authoring 118 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Sevilla, AN, Spain
Other Locations
Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: ZW25 (Zanidatamab), Palbociclib, Fulvestrant
Study Phase: Phase 2
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

118 Total Publications

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Borrego-Ruiz's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile